All In Biotech

Drug Trial Radar · NCT06226714

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

A Randomized, Blinded, Peer-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 18-59 Years

Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

840

Actual

Start

Mar 1, 2024

Primary completion

Sep 26, 2024

Study completion Aug 2025

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups.

Conditions

  • Meningococcal Meningitis

Interventions

  • MCV4Biological

    1 dose of MCV4 on Day 0

  • MPSV4Biological

    1 dose of MSPV4 on Day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Meningococcal antibody positive conversion rates for groups A, C, Y, and W135 in all subjectsTime frame: 30 days post immunization
  2. Geometric mean titer (GMT) of antibodies to groups A, C, Y, and W135 in all subjectsTime frame: 30 days post immunization
  3. Incidence of adverse reactions in all subjectsTime frame: Within 30 mins after immunization
  4. Incidence of adverse reactions/events in all subjectsTime frame: 7 days post immunization
  5. Incidence of adverse reactions/events in all subjectsTime frame: Within 30 days after immunization

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Jiangjin District Center for Disease Control and Prevention

    Chongqing, China

  • Wanzhou District Center for Disease Control and Prevention

    Chongqing, China

  • Yuzhong District Center for Disease Control and Prevention

    Chongqing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.